Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4841609 | 0.95 | TRPA1 (0.36) | TRPA1MAPTPOLBRORCMAPK1 | |
| SCHEMBL4842813 | 0.94 | TRPA1 (0.37) | TRPA1MAPTPOLBRORCMAPK1 | |
| SCHEMBL4841408 | 0.94 | TRPA1 (0.36) | TRPA1MAPTPOLBRORCMAPK1 | |
| SCHEMBL4840502 | 0.94 | MAPT (0.39) | TRPA1MAPTPOLBRORCMAPK1 | |
| SCHEMBL4842704 | 0.93 | GNRHR (0.36) | TRPA1MAPTPOLBRORCMAPK1 | |
| SCHEMBL4838081 | 0.92 | MAPT (0.40) | TRPA1MAPTPOLBRORCMAPK1 | |
| SCHEMBL4833128 | 0.92 | TRPA1 (0.39) | TRPA1MAPTRORC | |
| SCHEMBL4832976 | 0.90 | MAPT (0.39) | TRPA1MAPTPOLBRORCMAPK1 | |
| SCHEMBL4838499 | 0.90 | TRPA1 (0.37) | TRPA1MAPTPOLBRORCMAPK1 | |
| SCHEMBL4833497 | 0.89 | TSHR (0.37) | TRPA1MAPTPOLBRORCMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465811-B2 | Indoline compounds | LABORATOIRES FOURNIER S.A. (FR) | 2008-12-16 | — | — | US | disclosed |
| US-20080119465-A1 | Novel Indoline Compounds | LABORATORIES FOURNIER S.A. (FR) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119465-A1 | Novel Indoline Compounds | GPR119, INSR, IRS1 | TRPA1 368/4885MAPT 763/4885POLB 4775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.